When is a single‑donor (apheresis) platelet unit indicated for a patient with severe thrombocytopenia (≤10 × 10⁹/L) or active bleeding, or before an invasive procedure requiring a platelet count of ≥50 × 10⁹/L?

Single-Donor (Apheresis) Platelet Transfusion

A single-donor apheresis platelet unit is the standard recommended dose for prophylactic transfusion in hospitalized adults with severe thrombocytopenia (≤10 × 10⁹/L) and for patients requiring platelet support before invasive procedures or with active bleeding. 1

Prophylactic Transfusion for Severe Thrombocytopenia

For hospitalized adults with therapy-induced hypoproliferative thrombocytopenia:

• Transfuse when platelet count ≤10 × 10⁹/L to reduce spontaneous bleeding risk 1
• Use up to one single apheresis unit (or equivalent pooled concentrate) as the standard dose 1
• Higher doses provide no additional benefit; lower doses (half-unit) are equally effective but require more frequent transfusions 1
• The standard apheresis unit contains approximately 3 × 10¹¹ platelets 2

This represents a strong recommendation with moderate-quality evidence from the AABB 2015 guidelines 1.

Pre-Procedure Platelet Thresholds

Single-donor apheresis platelets are indicated to achieve specific thresholds before invasive procedures:

Low-Risk Procedures

• Central venous catheter placement: Transfuse if <20 × 10⁹/L (weak recommendation, low-quality evidence) 1
• Recent observational data support this lower threshold even for large-bore apheresis catheters 1

Moderate-Risk Procedures

• Lumbar puncture: Transfuse if <50 × 10⁹/L (weak recommendation, very-low-quality evidence) 1
• This conservative threshold accounts for the devastating consequences of CNS hemorrhage 1
• Clinical judgment may allow procedures at 20-50 × 10⁹/L in selected patients 1

High-Risk Procedures

• Major elective nonneuraxial surgery: Transfuse if <50 × 10⁹/L (weak recommendation, very-low-quality evidence) 1
• Platelet counts ≥50 × 10⁹/L are considered safe for major surgery 1

Active Bleeding Management

For critically ill patients with clinically significant active bleeding and thrombocytopenia:

• Maintain platelet count >50 × 10⁹/L for severe bleeding 3
• Maintain platelet count >30 × 10⁹/L for non-severe bleeding (WHO grade ≥2) 3
• Single apheresis units are the standard product for therapeutic transfusion 1
• Clinical judgment should guide decisions based on bleeding site, severity, and patient-specific factors 3

Important caveat: For cardiac surgery with cardiopulmonary bypass, routine prophylactic transfusion is NOT recommended in non-thrombocytopenic patients. Transfuse only for perioperative bleeding with thrombocytopenia and/or platelet dysfunction 1.

Apheresis vs. Pooled Platelets: Clinical Equivalence with Risk Differences

While both single-donor apheresis and pooled whole-blood-derived platelets are clinically effective, they are not equivalent in terms of infection risk:

Infection Risk Profile

• Apheresis platelets expose patients to 1 donor 4
• Pooled concentrates expose patients to 4-8 donors 4
• For known pathogens (HIV, HCV, HBV), pooled concentrates carry 2.2-3.7 times higher relative risk 4
• For unknown or emerging pathogens (e.g., prions), the risk multiplies directly with donor exposure 4

Clinical Efficacy

• Transfusion efficacy is equivalent when comparing products of similar platelet content 2
• ABO-compatible platelets should be prioritized to improve increments and reduce refractoriness 2
• Both products are interchangeable for hemostatic effectiveness 2

Dosing Considerations

Body surface area-adjusted dosing may optimize outcomes:

• Low-dose: 1.41 × 10¹¹/m² is hemostatically effective but requires more frequent transfusions 2
• Median-dose: 2.4 × 10¹¹/m² may be more practical for outpatients to reduce clinic visits 2
• Standard single apheresis unit typically contains 3 × 10¹¹ platelets 2

Do not deviate from standard dosing (3 × 10¹¹ platelets) without compelling reason, as lower doses increase risk of WHO grade III-IV bleeding, particularly during induction chemotherapy 4.

Common Pitfalls to Avoid

1. Do not transfuse prophylactically at counts >10 × 10⁹/L in stable patients without bleeding or planned procedures—this increases unnecessary donor exposure 1

2. Do not use platelet count alone for cardiac surgery patients; transfuse based on clinical bleeding and evidence of platelet dysfunction 1

3. Do not assume all platelet products are equivalent—apheresis units minimize donor exposure and infection risk compared to pooled concentrates 4

4. Do not withhold transfusion in actively bleeding patients while waiting for specific thresholds—clinical bleeding severity should guide therapy 3

5. For RhD-negative females of childbearing potential receiving RhD-positive apheresis platelets, administer Rh immunoglobulin to prevent alloimmunization 2